Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Account Payables (2016 - 2025)

Iovance Biotherapeutics has reported Change in Account Payables over the past 7 years, most recently at -$5.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$5.2 million for Q4 2025, up 14.15% from a year ago — trailing twelve months through Dec 2025 was -$6.7 million (up 15.05% YoY), and the annual figure for FY2025 was -$6.7 million, up 15.05%.
  • Change in Account Payables for Q4 2025 was -$5.2 million at Iovance Biotherapeutics, down from -$4.4 million in the prior quarter.
  • Over the last five years, Change in Account Payables for IOVA hit a ceiling of $14.4 million in Q3 2024 and a floor of -$10.4 million in Q2 2024.
  • Median Change in Account Payables over the past 3 years was -$2.1 million (2023), compared with a mean of -$806166.7.
  • Peak annual rise in Change in Account Payables hit 247.82% in 2024, while the deepest fall reached 7216.44% in 2024.
  • Iovance Biotherapeutics' Change in Account Payables stood at $11.4 million in 2023, then crashed by 153.16% to -$6.1 million in 2024, then increased by 14.15% to -$5.2 million in 2025.
  • The last three reported values for Change in Account Payables were -$5.2 million (Q4 2025), -$4.4 million (Q3 2025), and $893000.0 (Q2 2025) per Business Quant data.